1. Grifoni, A., et al., A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host & Microbe, 2020. 27(4): p. 671-680.e2.
2. Wu, F., et al., A new coronavirus associated with human respiratory disease in China. Nature, 2020. 579(7798): p. 265-269.
3. Chen, Y., Q. Liu, and D. Guo, Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of medical virology, 2020. 92(4): p. 418-423.
4. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020. 395(10223): p. 497-506.
5. Young, B.E., et al., Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama, 2020. 323(15): p. 1488-1494.
6. Lima, C.M.A.d.O., Informações sobre o novo coronavírus (COVID-19). Radiologia Brasileira, 2020. 53(2): p. V-VI.
7. Lee, Y., et al., Prevalence and duration of acute loss of smell or taste in COVID-19 patients. Journal of Korean medical science, 2020. 35(18).
8. Hornuss, D., et al., Anosmia in COVID-19 patients. Clinical Microbiology and Infection, 2020.
9. Guan, W.-j., et al., Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. 2020. 55(5).
10. Wang, B., et al., Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY), 2020. 12(7): p. 6049.
11. Zhou, F., et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 2020.
12. Corey, L., et al., A strategic approach to COVID-19 vaccine R&D. Science, 2020. 368(6494): p. 948-950.
13. Yao, X., et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical infectious diseases, 2020. 71(15): p. 732-739.
14. Cyranoski, D., This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan. Nature, 2020.
15. Cohen, J., Vaccine wagers on coronavirus surface protein pay off. 2020, American Association for the Advancement of Science.
16. Mahase, E.J.B.B.M.J., Vaccinating the UK: how the covid vaccine was approved, and other questions answered. 2020. 371.
17. England, P.H., New and emerging respiratory virus threats advisory group (NERVTAG). 2020.
18. Taubenberger, J.K. and D.M. Morens, 1918 Influenza: the mother of all pandemics. Revista Biomedica, 2006. 17(1): p. 69-79.
19. Trilla, A., G. Trilla, and C. Daer, The 1918 “Spanish Flu” in Spain. Clinical Infectious Diseases, 2008. 47(5): p. 668-673.
20. Wang, L., A. Zou, and J. Wang, Matrix analysis of clinical characteristics and dynamic observation of immunological features in 90 cases of COVID-19. SSRN 2020, published online April 02.
21. Guo, C., et al., Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. BioRxiv, 2020.
22. Voineagu, I., et al., Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature, 2011. 474(7351): p. 380-384.
23. Xiong, Y., et al., Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes & infections, 2020. 9(1): p. 761-770.
24. Cock, P.J.A., et al., The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants. Nucleic Acids Research, 2010. 38(6): p. 1767-1771.
25. Kim, D., B. Langmead, and S.L. Salzberg, HISAT: a fast spliced aligner with low memory requirements. Nature Methods, 2015. 12(4): p. 357-360.
26. Audic, S. and J.-M. Claverie, The significance of digital gene expression profiles. Genome research, 1997. 7(10): p. 986-995.
27. Thaker, S.K., J. Ch’ng, and H.R. Christofk, Viral hijacking of cellular metabolism. BMC biology, 2019. 17(1): p. 1-15.
28. Channappanavar, R., et al., Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell host & microbe, 2016. 19(2): p. 181-193.
29. Sanjuán, R. and P. Domingo-Calap, Mechanisms of viral mutation. Cellular and Molecular Life Sciences, 2016. 73(23): p. 4433-4448.
30. Zhang, B., et al., Clinical characteristics of 82 death cases with COVID-19. MedRxiv, 2020.
31. Wen, W., et al., Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell discovery, 2020. 6(1): p. 1-18.
32. Sadanandam, A., et al., A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell Death Discovery, 2020. 6(1): p. 141.
33. Zhang, Y., et al., Interferon-induced transmembrane protein 3 genetic variant rs12252-C associated with disease severity in coronavirus disease 2019. The Journal of infectious diseases, 2020. 222(1): p. 34-37.
34. Feeley, E.M., et al., IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog, 2011. 7(10): p. e1002337.
35. Zheng, H.-Y., et al., Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19. Signal Transduction and Targeted Therapy, 2020. 5(1): p. 294.
36. Lee, J.S., et al., Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Science Immunology, 2020. 5(49): p. eabd1554.
37. Zheng, Y., et al., A human circulating immune cell landscape in aging and COVID-19. Protein & Cell, 2020. 11(10): p. 740-770.
38. Arunachalam, P.S., et al., Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science, 2020. 369(6508): p. 1210.
39. Ren, X., et al., COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell, 2021.
40. Liu, J., et al., Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. Journal of medical virology, 2020. 92(5): p. 491-494.
41. Channappanavar, R. and S. Perlman. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. in Seminars in immunopathology. 2017. Springer.
42. Gu, J., et al., Multiple organ infection and the pathogenesis of SARS. Journal of Experimental Medicine, 2005. 202(3): p. 415-424.
43. Nicholls, J.M., et al., Lung pathology of fatal severe acute respiratory syndrome. The Lancet, 2003. 361(9371): p. 1773-1778.
44. Villani, A.C., et al., Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science, 2017. 356(6335).
45. Blanco-Melo, D., et al., Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 2020. 181(5): p. 1036-1045.e9.
46. de Melo, C.V.B., et al., Transcriptomic dysregulations associated with SARS-CoV-2 infection in human nasopharyngeal and peripheral blood mononuclear cells. bioRxiv, 2020: p. 2020.09.09.289850.
47. Bailey, M.H., et al., Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018. 173(2): p. 371-385.e18.
48. Li, G., et al., Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. Computational and Structural Biotechnology Journal, 2021. 19: p. 1-15.
49. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. 2020. 395(10223): p. 507-513.
50. Liu, T., et al., Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity. Frontiers in microbiology, 2020. 11: p. 603509-603509.